Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals (Nasdaq: TNXP) reported Q2 2025 financial results and operational highlights, with key focus on their lead candidate TNX-102 SL for fibromyalgia, which has an FDA PDUFA date of August 15, 2025. The company reported $125.3 million in cash and cash equivalents as of June 30, 2025.
Q2 2025 financial results showed net product revenue of $2.0 million and a net loss of $28.3 million ($3.86 per share). The company's cash runway is expected to extend into Q3 2026, supported by recent equity offerings that raised $51.5 million in net proceeds.
Notable developments include the company's addition to the Russell 3000® and Russell 2000® Indexes, publication of positive Phase 3 RESILIENT trial results in Pain Medicine, and progress across their CNS and immunology pipeline, including TNX-1500 and TNX-801.
Tonix Pharmaceuticals (Nasdaq: TNXP) ha riportato i risultati finanziari e gli aggiornamenti operativi del secondo trimestre 2025, con particolare attenzione al candidato di punta TNX-102 SL per la fibromialgia, la cui data PDUFA è il 15 agosto 2025. La società ha dichiarato di avere $125.3 million in contanti e equivalenti al 30 giugno 2025.
I risultati del 2T 2025 hanno evidenziato un ricavo netto da prodotti di $2.0 million e una perdita netta di $28.3 million ($3.86 per azione). La liquidità dovrebbe coprire l'azienda fino al terzo trimestre 2026, supportata da recenti offerte azionarie che hanno raccolto $51.5 million di proventi netti.
Tra gli sviluppi rilevanti figurano l'ingresso negli indici Russell 3000® e Russell 2000®, la pubblicazione su Pain Medicine dei risultati positivi della fase 3 RESILIENT e i progressi nel portafoglio CNS e immunologia, inclusi TNX-1500 e TNX-801.
Tonix Pharmaceuticals (Nasdaq: TNXP) informó sus resultados financieros y aspectos operativos del segundo trimestre de 2025, con énfasis en su candidato principal TNX-102 SL para fibromialgia, cuya fecha PDUFA es el 15 de agosto de 2025. La compañía declaró $125.3 million en efectivo y equivalentes al 30 de junio de 2025.
Los resultados del 2T 2025 mostraron un ingreso neto por productos de $2.0 million y una pérdida neta de $28.3 million ($3.86 por acción). Se espera que la liquidez alcance hasta el tercer trimestre de 2026, respaldada por recientes emisiones de acciones que recaudaron $51.5 million en ingresos netos.
Entre los desarrollos destacados están la inclusión en los índices Russell 3000® y Russell 2000®, la publicación en Pain Medicine de los resultados positivos del ensayo RESILIENT de fase 3 y los avances en su cartera de SNC e inmunología, incluidos TNX-1500 y TNX-801.
Tonix Pharmaceuticals (Nasdaq: TNXP)는 2025년 2분기 재무 결과 및 운영 하이라이트를 발표했으며, 핵심 후보물질 TNX-102 SL(섬유근통증 치료제)에 대한 FDA PDUFA 마감일이 2025년 8월 15일입니다. 회사는 2025년 6월 30일 기준 $125.3 million의 현금 및 현금성 자산을 보고했습니다.
2025년 2분기 실적은 제품 순매출 $2.0 million과 순손실 $28.3 million(주당 $3.86)을 기록했습니다. 최근 주식 발행으로 순수익 $51.5 million을 확보해 현금 소진 시점은 2026년 3분기까지 연장될 것으로 예상됩니다.
주요 개발 사항으로는 Russell 3000® 및 Russell 2000® 지수 편입, Pain Medicine에 RESILIENT 3상 긍정적 결과 게재, 그리고 중추신경계(CNS)와 면역학 파이프라인에서의 진전(예: TNX-1500, TNX-801)이 포함됩니다.
Tonix Pharmaceuticals (Nasdaq: TNXP) a publié ses résultats financiers et faits marquants opérationnels du deuxième trimestre 2025, en mettant l’accent sur son candidat principal TNX-102 SL pour la fibromyalgie, dont la date PDUFA est le 15 août 2025. La société a déclaré disposer de $125.3 million en liquidités et équivalents au 30 juin 2025.
Les résultats du T2 2025 montrent un chiffre d’affaires net produit de $2.0 million et une perte nette de $28.3 million (3,86 $ par action). La trésorerie devrait permettre de poursuivre les activités jusqu’au troisième trimestre 2026, soutenue par des augmentations de capital récentes ayant levé $51.5 million de produit net.
Parmi les faits marquants figurent l’inclusion de la société dans les indices Russell 3000® et Russell 2000®, la publication dans Pain Medicine des résultats positifs de l’essai RESILIENT de phase 3 et les progrès du portefeuille SNC et immunologie, comprenant TNX-1500 et TNX-801.
Tonix Pharmaceuticals (Nasdaq: TNXP) berichtete die Finanzergebnisse und operativen Highlights für das zweite Quartal 2025, mit Schwerpunkt auf dem führenden Kandidaten TNX-102 SL für Fibromyalgie, dessen PDUFA-Datum der 15. August 2025 ist. Das Unternehmen gab zum 30. Juni 2025 $125.3 million an Zahlungsmitteln und Zahlungsmitteläquivalenten an.
Die Ergebnisse des 2. Quartals 2025 wiesen einen Netto-Produktumsatz von $2.0 million und einen Nettoverlust von $28.3 million ($3.86 je Aktie) aus. Die Cash-Runway dürfte sich bis ins 3. Quartal 2026 erstrecken und wird durch jüngste Aktienplatzierungen gestützt, die $51.5 million an Nettoerlösen einbrachten.
Zu den bemerkenswerten Entwicklungen zählen die Aufnahme in die Russell 3000®- und Russell 2000®-Indizes, die Veröffentlichung positiver Phase-3-RESILIENT-Ergebnisse in Pain Medicine sowie Fortschritte im CNS- und Immunologie-Portfolio, einschließlich TNX-1500 und TNX-801.
- FDA PDUFA date approaching for TNX-102 SL with potential to be first new fibromyalgia drug in 16 years
- Strong cash position of $125.3 million plus additional $51.5 million from equity offerings
- Positive Phase 3 RESILIENT trial results published in peer-reviewed journal
- Addition to Russell 3000® and Russell 2000® Indexes enhancing visibility
- Pipeline advancement with positive TNX-1500 Phase 1 data and TNX-801 preclinical results
- Net loss increased to $28.3 million in Q2 2025
- Product revenue declined to $2.0 million from $2.2 million year-over-year
- Operating expenses increased significantly to $30.3 million from $79.5 million year-over-year
- SG&A expenses more than doubled to $16.2 million from $7.5 million due to pre-launch activities
Insights
Tonix nears FDA decision for first new fibromyalgia drug in 16+ years with strong $125.3M cash position through Q3 2026.
Tonix Pharmaceuticals approaches a pivotal regulatory milestone with the FDA decision on TNX-102 SL for fibromyalgia expected by August 15, 2025. This represents the first potential new treatment approval for fibromyalgia in over 16 years, addressing a serious unmet medical need in a condition the FDA has designated for Fast Track review.
The company's financial position remains solid with $125.3 million in cash as of June 30, 2025, up from $98.8 million at year-end 2024. With an additional $51.5 million raised in Q3, management projects runway into Q3 2026, providing sufficient capital to potentially launch TNX-102 SL if approved. This financial stability comes despite increasing cash burn, with $31.4 million used in operations during H1 2025 compared to $27.5 million in H1 2024.
Q2 product revenue was $2.0 million from migraine products, slightly down from $2.2 million in Q2 2024. The $28.3 million quarterly net loss ($3.86 per share) reflects significantly increased SG&A expenses of $16.2 million (up from $7.5 million year-over-year), primarily due to pre-launch activities for TNX-102 SL. R&D expenses also increased to $10.8 million from $9.7 million in Q2 2024.
Beyond the lead program, Tonix continues advancing its pipeline with the DoD-funded Phase 2 OASIS trial of TNX-102 SL for acute stress reaction now enrolling, positive Phase 1 data for TNX-1500 (anti-CD40L antibody) supporting advancement to Phase 2 in kidney transplantation, and promising preclinical data for TNX-801 vaccine showing durable protection against mpox. The company's inclusion in the Russell 3000® and Russell 2000® indexes in June 2025 provides additional validation and potential for increased institutional investor interest.
FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first new drug for fibromyalgia in more than 16 years
In June 2025, the Company was added to the Russell 3000® and Russell 2000® Indexes following the annual reconstitution
Phase 3 RESILIENT results published in peer-reviewed journal, Pain Medicine, including statistically significant reduction in fibromyalgia pain with once‑nightly TNX‑102 SL; generally well tolerated
Cash and cash equivalents of
CHATHAM, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced financial results for the second quarter ended June 30, 2025, and provided an overview of recent operational highlights.
“With the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of August 15, for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, we are excited about the potential to make this important new therapy available to patients in the fourth quarter of this year,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “FDA considers fibromyalgia a serious condition and awarded TNX-102 SL Fast Track designation last year. There has been no new treatment for this debilitating condition approved in over 16 years. Additionally, our RESILIENT Phase 3 study results were recently published in the peer-reviewed journal, Pain Medicine.”
Dr. Lederman continued, “Our pipeline momentum remains strong. In the second quarter, we dosed the first patient in the U.S. Department of Defense (DoD)-funded, investigator-initiated, OASIS trial of TNX-102 SL for acute stress reaction. We also presented new data for our live-virus vaccine, TNX-801, which demonstrated durable single-dose protection against mpox and rabbitpox in animal models. We previously reported positive Phase 1 safety and pharmacokinetic data for TNX-1500, advancing this next-generation anti-CD40L antibody toward a Phase 2 kidney-transplant study. We are well-positioned to translate these milestones into meaningful value for patients and shareholders alike.”
| Key Investigational Product Candidates |
Central Nervous System (CNS) Pipeline
TNX-102 SL (cyclobenzaprine HCl sublingual tablets 2.8 mg): two tablets (5.6 mg), once-daily at bedtime for fibromyalgia (FM) – a centrally-acting, non-opioid
analgesic.
- In June 2025, Tonix presented a poster at the European Congress of Rheumatology (EULAR 2025) demonstrating that TNX‑102 SL produced statistically significant, durable (14‑week) pain reduction across two Phase 3 trials.
- In July 2025, Tonix announced online publication of full results from the confirmatory Phase 3 RESILIENT trial of TNX‑102 SL in the peer-reviewed journal Pain Medicine, showing once‑nightly 5.6 mg achieved a statistically significant reduction in fibromyalgia pain versus placebo and was well tolerated; the data confirm the earlier RELIEF study and support the ongoing New Drug Application (NDA) review with an August 15, 2025 PDUFA goal date.
TNX-102 SL in development for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD)
- In May 2025, the first patient was dosed in the Phase 2 investigator initiated OASIS trial evaluating a two week course of TNX102 SL 5.6 mg to reduce the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD); the study is sponsored by the University of North Carolina and supported by a
$3 million U.S. Department of Defense grant, with topline results expected in the second half of 2026.
| Immunology Pipeline |
TNX-1500 (anti-CD40L Fc-modified humanized monoclonal antibody): third generation anti-CD40L monoclonal antibody under investigation for prophylaxis for organ transplant rejection and treatment of autoimmune disorders
- In May 2025, Tonix reported positive topline data from a Phase 1 single‑ascending‑dose study in healthy volunteers: TNX‑1500 met all safety, pharmacokinetic and pharmacodynamic goals, blocked primary and secondary antibody responses at 10 mg/kg and 30 mg/kg doses with intravenous (i.v.) administration, and showed a 34–38‑day mean half‑life that supports monthly i.v. dosing—supporting the path for a planned Phase 2 study to evaluate TNX-1500 for prevention of rejection in kidney allogeneic transplant.
TNX-801 (recombinant horsepox virus, minimally replicative live-virus vaccine): potential vaccine to protect against mpox and smallpox.
- In April 2025, Tonix presented new preclinical data on TNX-801 at the World Vaccine Congress Washington 2025 showing a single subcutaneous (s.c.) dose protected animals from mpox and rabbitpox for at least six months, remained well tolerated even in immunocompromised models, and met key attributes in the WHO’s preferred target product profile for mpox vaccines.
| Corporate and Partnerships |
- In May 2025, Tonix appointed Joseph Hand, Esq. as General Counsel and Executive Vice President of Operations, adding more than two decades of legal and operational expertise as the Company prepares for potential TNX‑102 SL commercialization.
- In June 2025, Tonix announced that commercial veteran James Hunter joined its Board of Directors, bringing forty years of go‑to‑market experience to strengthen strategy and governance ahead of the expected TNX‑102 SL launch.
- In June 2025, the Company was added to the Russell 3000® and Russell 2000® Indexes following the annual reconstitution, broadening visibility among institutional investors as Tonix approaches key regulatory milestones.
| Financials |
As of June 30, 2025, Tonix had
The Company believes that, based on its current operating plan, its cash on hand at June 30, 2025, together with
Second Quarter 2025 Financial Results
Net product revenue for the three months ended June 30, 2025 was approximately
Research and development expenses for the three months ended June 30, 2025 were
Selling, general and administrative expenses for the three months ended June 30, 2025 were
Net loss available to common stockholders was
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for fibromyalgia and for which a PDUFA goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA had also granted Fast Track designation to TNX-102 SL for fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
| TONIX PHARMACEUTICALS HOLDING CORP. | |||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||
| (Dollars In Thousands Except Per Share Amounts) | |||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||
| REVENUE: | |||||||||||||
| Product revenues, net | $ | 1,998 | $ | 2,208 | $ | 4,427 | $ | 4,690 | |||||
| COSTS AND EXPENSES: | |||||||||||||
| Cost of sales | 3,272 | 3,367 | 4,215 | 5,027 | |||||||||
| Research and development | 10,820 | 9,698 | 18,256 | 22,561 | |||||||||
| General and administrative | 16,202 | 7,502 | 26,306 | 16,812 | |||||||||
| Asset impairment charges | - | 58,957 | - | 58,957 | |||||||||
| Total operating expenses | 30,294 | 79,524 | 48,777 | 103,357 | |||||||||
| Operating Loss | (28,296 | ) | (77,316 | ) | (44,350 | ) | (98,667 | ) | |||||
| Grant income | 1,036 | - | 1,959 | - | |||||||||
| (Loss) gain on change in fair value of warrant liabilities | - | (855 | ) | - | 6,150 | ||||||||
| Loss on Extinguishment | - | - | (2,092 | ) | - | ||||||||
| Interest income, net | 943 | - | 1,571 | - | |||||||||
| Other expense, net | (1,955 | ) | (605 | ) | (2,189 | ) | (1,198 | ) | |||||
| Net loss available to common stockholders | $ | (28,272 | ) | $ | (78,776 | ) | $ | (45,101 | ) | $ | (93,715 | ) | |
| Net loss per common share, basic and diluted | $ | (3.86 | ) | $ | (1,920.84 | ) | $ | (6.80 | ) | $ | (2,720.43 | ) | |
| Weighted average common shares outstanding, basic and diluted | 7,327,257 | 41,011 | 6,631,111 | 34,449 | |||||||||
| TONIX PHARMACEUTICALS HOLDING CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) (Unaudited) | ||||||||
| June 30, 2025 | December 31, 20241 | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 125,331 | $ | 98,776 | ||||
| Accounts receivable, net | 2,320 | 3,683 | ||||||
| Inventory | 5,986 | 8,408 | ||||||
| Prepaid expenses and other | 9,898 | 8,135 | ||||||
| Total current assets | 143,535 | 119,002 | ||||||
| Other non-current assets | 43,824 | 43,888 | ||||||
| Total assets | $ | 187,359 | $ | 162,890 | ||||
| Liabilities and stockholders' equity | ||||||||
| Total liabilities | $ | 19,358 | $ | 23,332 | ||||
| Stockholders' equity | 168,001 | 139,558 | ||||||
| Total liabilities and stockholders' equity | $ | 187,359 | $ | 162,890 | ||||
1The condensed consolidated balance sheet for the year ended December 31, 2024 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.
Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599
Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com
Media Contact
Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432
Indication and Usage
Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.
Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.
Important Safety Information
Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:
- discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
- severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
- pain or discomfort in your arms, back, neck, jaw or stomach
- shortness of breath with or without chest discomfort
- breaking out in a cold sweat
- nausea or vomiting
- feeling lightheaded
Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.
Do not use Zembrace or Tosymra if you have:
- history of heart problems
- narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
- uncontrolled high blood pressure
- hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
- had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
- severe liver problems
- taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
- are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
- an allergy to sumatriptan or any of the components of Zembrace or Tosymra
Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.
Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.
Zembrace and Tosymra may cause serious side effects including:
- changes in color or sensation in your fingers and toes
- sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
- cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
- increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
- medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
- serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
- hives (itchy bumps); swelling of your tongue, mouth, or throat
- seizures even in people who have never had seizures before
The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).
Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.
This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.
You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
FAQ
What is the PDUFA date for Tonix's TNX-102 SL fibromyalgia drug?
What were Tonix Pharmaceuticals' (TNXP) Q2 2025 financial results?
How long will Tonix's current cash runway last?
What were the key pipeline developments for TNXP in Q2 2025?
How did Tonix's operating expenses change in Q2 2025?
